Who is sponsoring NCT07103447?

NCT07103447 is sponsored by Shuangyue Liu.

What condition does NCT07103447 study?

NCT07103447 studies Breast Cancer - Female.

What drugs are being tested in NCT07103447?

Interventions: AK112, Carboplatin, Paxlitaxel.

What is the status of NCT07103447?

NCT07103447 is currently NOT_YET_RECRUITING.

Last reviewed 2025-08-05 · How we verify

Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC

NCT07103447 PHASE2 NOT_YET_RECRUITING

This prospective, multicenter, single-arm clinical study aims to evaluate the efficacy and safety of AK112 in combination with albumin-bound paclitaxel and carboplatin as neoadjuvant treatment in adult women with early or locally advanced triple-negative breast cancer (TNBC). The study seeks to address the pathological complete response (pCR) rate, objective response rate (ORR), breast conservation rate, and invasive disease-free survival (iDFS) following treatment with AK112 combined with albumin-bound paclitaxel and carboplatin in early or locally advanced TNBC.

Details

Lead sponsor	Shuangyue Liu
Phase	PHASE2
Status	NOT_YET_RECRUITING
Enrolment	54
Start date	Wed Sep 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Dec 31 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Breast Cancer - Female

Interventions

AK112, Carboplatin, Paxlitaxel